. 2021 Feb 25;11:625688. doi: 10.3389/fonc.2021.625688

Table 2.

Univariate analysis of factors potentially associated with overall survival outcomes.

Variable	No.	Median OS	Overall survival rate (%)			P Value
Variable	No.	Median OS	1 y	2 y	3 y	P Value
Gender						0.022
Male	154	12.0	50.0	17.9	7.5
Female	89	15.0	61.8	22.4	18.0
Age (years)						0.334
<60	172	13.7	57.6	19.7	10.5
≥60	71	11.6	46.5	18.9	12.9
Tumor histology						0.388
Squamous	78	13.0	51.3	16.3	4.1
Nonsquamous	165	13.4	55.8	20.8	14.8
History of smoking						0.078
Yes	128	12.0	46.9	18.5	8.0
No	115	15.0	62.6	20.8	15.3
weight loss >5% in the last 6 months						0.339
Yes	52	15.0	67.2	24.4	8.7
No	191	12.1	50.8	18.3	11.8
KPS						0.002
< 80	21	7.0	28.6	4.8	0
≥ 80	222	13.6	56.8	21.0	12.5
T stage						0.009
T_1-2	69	14.7	44.9	22.6	14.6
T_3-4	174	11.0	58.0	11.8	0
N stage						0.880
N_0-1	29	13.0	58.6	10.3	0
N_2-3	214	13.0	53.7	20.9	12.3
No. of metastatic organs						0.018
≤2	182	13.7	57.7	23.0	13.5
>2	61	11.3	44.3	9.1	4.6
Total number of metastases						0.000
< 5	172	60.5	24.3	14.5	15.2
≥ 5	71	39.4	5.6	4.2	11.0
Brain metastasis						0.000
Yes	90	11.0	44.4	7.6	2.5
No	153	15.2	59.5	26.7	16.6
Bone metastasis						0.054
Yes	125	12.0	48.8	14.1	9.7
No	118	15.0	60.2	25.4	12.8
Liver metastasis						0.669
Yes	24	11.6	41.7	16.7	11.1
No	219	13.6	55.7	19.9	11.4
Contralateral lung metastasis						0.408
Yes	78	12.0	50.0	19.7	7.8
No	168	13.4	56.4	19.4	12.9
Radiotherapy doseGy						0.001
<60	112	42.0	12.6	8.7	11.0
≥60	131	64.9	24.0	13.9	16.0
Radiotherapy technology						0.783
3DCRT	85	54.1	17.3	3.8	14.0
IMRT	158	54.4	19.2	14.4	12.7
Radiation to metastases						0.582
Yes	157	54.8	18.3	10.6	13.0
No	86	53.5	19.6	12.7	13.4
No. of chemotherapy cycle						0.003
<4	122	10.0	40.2	14.9	10.2
≥4	121	16.0	68.6	23.4	13.4
D-Dimer (mg/L)						0.040
<0.5	118	16.0	61.0	21.5	13.2
≥0.5	125	12.0	48.0	18.0	9.5
Fibrinogen, g/L						0.000
≤4.50	175	15.0	62.3	23.1	14.0
>4.50	68	9.0	33.8	10.1	4.0
WBC count, ×10⁹/L						0.030
≤7.5	165	15.0	63.0	21.5	11.2
>7.5	78	9.1	35.9	15.4	10.8
Hb level, g/L						0.000
≤120	80	9.7	37.5	11.3	6.5
>120	163	16.0	62.6	22.8	13.6
PLT count, ×10⁹/L						0.001
≤220	112	16.0	67.0	25.7	15.9
>220	131	11.0	43.5	14.2	7.3
Neutrophil absolute value, ×10⁹/L						0.000
≤5.8	176	15.0	63.1	22.4	12.6
>5.8	67	9.0	31.3	11.9	6.8
Lymphocyte absolute value, ×10⁹/L						0.094
≤0.93	43	10.0	34.9	12.4	9.3
>0.93	200	14.0	58.5	21.1	11.6
Neutrophil-to-lymphocyte ratio						0.001
≤4.30	149	15.2	62.4	25.6	15.2
>4.30	94	11.0	41.5	10.1	5.4
Serum calcium level, nmol/L						0.131
≤2.35	150	12.0	50.0	18.8	9.7
>2.35	93	15.0	61.2	20.6	11.9
Albumin, g/L						0.048
≤40	64	9.0	40.6	16.8	8.7
>40	179	14.0	59.2	20.6	12.2
LDH, U/L						0.062
≤165	61	16.7	67.2	27.7	12.0
>165	182	12.0	50.0	16.8	11.0
ALP level, U/L						0.009
≤100	129	15.4	62.0	26.5	15.7
>100	114	11.6	45.6	11.6	7.4
Maximum diameter of primary tumor						0.130
≤3.65 cm	91	12.0	46.2	17.3	9.7
>3.65 cm	152	14.7	59.2	20.9	12.3